As a unique product of gene rearrangement in CML, the BCR-ABL1 oncoprotein can be exploited as an immunogenic target in addition to being a molecular target for inhibitors. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.